Market Report

mRNA Cancer Vaccine Market Report 2026-2036

The global mRNA Cancer Vaccine market is projected to grow at a CAGR of 27.1% by 2036

SKU: PHA1384 Category: Code: PHA1384
Clear
← Back to category Therapeutic Drugs

Description

Visiongain has published a new report, mRNA Cancer Vaccine Market Report 2026-2036, providing a comprehensive analysis of the global mRNA cancer vaccine market, including market size, growth drivers, competitive positioning, and revenue forecasts across key segments.

The global mRNA cancer vaccine market is expected to surpass US$1,200.0 million in 2026, with strong growth projected through to 2036, driven by increasing adoption of precision oncology, advances in sequencing technologies, and expanding clinical pipelines.

This growth is supported by the ability of mRNA platforms to enable personalised, targeted immunotherapies based on tumour genomics, alongside continued innovation in neoantigen identification and delivery technologies.

Access a Free Sample of This Report

Download a sample to explore:

  • Market forecasts and segment breakdowns
  • Competitive and company-level insights
  • Key trends shaping the market
  • Trade, policy, and supply chain analysis

Download Free Sample Report

Technological Innovation Driving Market Expansion

Advances in genomic sequencing and neoantigen prediction are accelerating the development of personalised mRNA cancer vaccines. These technologies enable precise targeting of tumour-specific mutations, improving therapeutic effectiveness and supporting integration into precision oncology workflows.

At the same time, platform innovations such as self-amplifying mRNA and improved delivery systems are enhancing scalability and reducing development timelines, positioning mRNA vaccines as a key modality in next-generation oncology treatments.

Trade, Policy & Supply Chain Dynamics

The mRNA cancer vaccine market is increasingly shaped by global trade dynamics, regulatory frameworks, and supply chain dependencies.

Production relies on specialised inputs including lipid nanoparticles, nucleotides, and enzymes sourced globally. Tariffs and trade restrictions may increase costs and disrupt supply chains, impacting development timelines and pricing.

In parallel, regulatory requirements and cross-border collaboration play a critical role in clinical development and commercialisation, influencing market access and speed to market.

Commercial Impact

  • Cost and pricing pressure: Rising input and manufacturing costs may impact therapy affordability
  • Supply chain shifts: Increased focus on regional manufacturing and sourcing resilience
  • Regulatory influence: Approval pathways and compliance shape development timelines
  • Competitive positioning: Companies with scalable platforms and strong partnerships are better positioned

Company Intelligence

The mRNA cancer vaccine market is characterised by a mix of established biotechnology leaders and emerging innovators competing across platform capability, clinical progress, and strategic partnerships.

Leading companies including BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology are advancing their positions through clinical development, platform innovation, and collaboration.

Competition is increasingly defined by:

  • Technology and platform differentiation
  • Clinical pipeline strength
  • Manufacturing capability and scalability
  • Strategic partnerships and collaborations

This report analyses how competitive positioning is evolving, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • How is the mRNA cancer vaccine market evolving?
  • What is driving and restraining market growth?
  • Which segments and regions will generate the most revenue?
  • How will trade, policy, and supply chain dynamics impact the market?
  • Who are the leading companies and what are their prospects?

Report Scope and Data Coverage

  • Global mRNA cancer vaccine market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across vaccine type, therapeutic approach, phase, indication, and end-user
  • Regional and national market forecasts
  • Competitive intelligence on leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

CTA

Segmentation Framework

By Vaccine Type

  • Personalised
  • Semi-Personalised
  • Off-the-Shelf

By Therapeutic Approach

  • Monotherapy
  • Combination Therapy

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • High TMB Solid Tumors
  • GI Cancers
  • Gynecological Cancers
  • Breast Cancer
  • Other Solid Tumours

By End-user

  • Biopharma & Biotechnology Companies
  • Contract Development & Manufacturing Organisations (CDMOs)
  • Research Institutes & Academic Centres
  • Hospitals & Specialised Cancer Centres

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of MEA

mRNA Cancer Vaccine Market Report 2026-2036
Need industry data? Please contact us today.

Company Intelligence Coverage

This report includes detailed profiles of leading companies such as:

  • Acuitas
  • Arcturus Therapeutics
  • BioNTech
  • Cartesian Therapeutics Inc
  • Chimeron Bio
  • eTheRNA
  • Ethris GmbH
  • ImmuneSensor Therapeutics
  • Moderna
  • Orna Therapeutics
  • Replimune Group
  • Sana Biotechnology
  • ST Pharm
  • Strand Therapeutics

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The mRNA cancer vaccine market is evolving rapidly, driven by precision medicine, technological innovation, and changing global supply dynamics.
  • Organisations that understand these trends will be better positioned to capture growth opportunities, manage risk, and strengthen competitive positioning.

Access the Full Forecast and Competitive Analysis

Purchase the mRNA Cancer Vaccine Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.

Download sample or contact us for enterprise access

For enterprise licensing, customised segmentation or analyst briefings, contact Visiongain directly at contactus@visiongain.com

Government Registration
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to mRNA Cancer Vaccine Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Executive Summary

3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.3 Impact Analysis
3.3.1 Market Driving Factors
3.3.1.1 Late-Stage Clinical Validation Strengthening Commercial Confidence
3.3.1.2 Dedicated Oncology Manufacturing and Automation Scale-Up
3.3.1.3 Strategic Big Pharma Alliances and Capital Deployment
3.3.2 Market Restraining Factors
3.3.2.1 Operational Complexity of Individualized Vaccine Workflows
3.3.2.2 Regulatory and Reimbursement Uncertainty for Novel Oncology Platforms
3.3.2.3 Competitive Landscape of Established and Emerging Immunotherapies
3.3.3 Market Opportunities
3.3.3.1 Expansion into Early-Stage and Adjuvant Cancer Settings
3.3.3.2 Platform Replicability Across Multiple Tumor Types
3.3.3.3 Strengthening mRNA Oncology Ecosystem and Infrastructure Investment
3.4 U.S. Tariffs: What’s the Impact on Global mRNA Cancer Vaccine Market?
3.4.1 Overview
3.4.2 V-Shaped Recovery Scenario
3.4.2.1 Why V-Shaped Recovery?
3.4.2.2 Impact from Tariffs
3.4.2.3 Market Dynamics and Demand Recovery
3.4.2.4 Policy and Funding Support
3.4.3 U-Shaped Recovery Scenario
3.4.3.1 Why U-Shaped Recovery?
3.4.3.2 Impact from Tariffs
3.4.3.3 Timeframe for Recovery
3.4.3.4 Policy and Funding Support
3.4.4 L Shaped Recovery Scenario
3.4.4.1 Why L-Shaped Recovery?
3.4.4.2 Impact from Tariffs
3.4.4.3 Market Dynamics and Demand Recovery
3.4.4.4 Policy and Funding Support
3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026–2031) and Long-term (2026–2036) Planning?
3.4.6 Impact of U.S. and China Trade War on mRNA Cancer Vaccine Market
3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
3.5 Porter’s Five Forces Analysis
3.5.1 Bargaining Power of Suppliers
3.5.2 Bargaining Power of Buyers
3.5.3 Competitive Rivalry
3.5.4 Threat of Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis

4 mRNA Cancer Vaccine Market Analysis by Indication
4.1 Key Findings
4.2 Indication Segment: Market Attractiveness Index
4.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
4.4 High TMB Solid Tumors
4.4.1 Market Size by Region, 2026-2036 (US$ Million)
4.4.2 Market Share by Region, 2026 & 2036 (%)
4.5 GI Cancers
4.5.1 Market Size by Region, 2026-2036 (US$ Million)
4.5.2 Market Share by Region, 2026 & 2036 (%)
4.6 Gynecological Cancers
4.6.1 Market Size by Region, 2026-2036 (US$ Million)
4.6.2 Market Share by Region, 2026 & 2036 (%)
4.7 Breast Cancers
4.7.1 Market Size by Region, 2026-2036 (US$ Million)
4.7.2 Market Share by Region, 2026 & 2036 (%)
4.8 Other Solid Tumors
4.8.1 Market Size by Region, 2026-2036 (US$ Million)
4.8.2 Market Share by Region, 2026 & 2036 (%)

5 mRNA Cancer Vaccine Market Analysis by Platform Type
5.1 Key Findings
5.2 Platform Type Segment: Market Attractiveness Index
5.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
5.4 Personalized
5.4.1 Market Size by Region, 2026-2036 (US$ Million)
5.4.2 Market Share by Region, 2026 & 2036 (%)
5.5 Off-the-Shelf
5.5.1 Market Size by Region, 2026-2036 (US$ Million)
5.5.2 Market Share by Region, 2026 & 2036 (%)
5.6 Semi-Personalized
5.6.1 Market Size by Region, 2026-2036 (US$ Million)
5.6.2 Market Share by Region, 2026 & 2036 (%)

6 mRNA Cancer Vaccine Market Analysis by Therapeutic Approach
6.1 Key Findings
6.2 Therapeutic Approach Segment: Market Attractiveness Index
6.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
6.4 Monotherapy
6.4.1 Market Size by Region, 2026-2036 (US$ Million)
6.4.2 Market Share by Region, 2026 & 2036 (%)
6.5 Combination Therapy
6.5.1 Market Size by Region, 2026-2036 (US$ Million)
6.5.2 Market Share by Region, 2026 & 2036 (%)

7 mRNA Cancer Vaccine Market Analysis by Phases
7.1 Key Findings
7.2 Phases Segment: Market Attractiveness Index
7.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
7.4 Phase I
7.4.1 Market Size by Region, 2026-2036 (US$ Million)
7.4.2 Market Share by Region, 2026 & 2036 (%)
7.5 Phase II
7.5.1 Market Size by Region, 2026-2036 (US$ Million)
7.5.2 Market Share by Region, 2026 & 2036 (%)
7.6 Phase III
7.6.1 Market Size by Region, 2026-2036 (US$ Million)
7.6.2 Market Share by Region, 2026 & 2036 (%)
7.7 Phase IV
7.7.1 Market Size by Region, 2026-2036 (US$ Million)
7.7.2 Market Share by Region, 2029 & 2036 (%)

8 mRNA Cancer Vaccine Market Analysis by End-users
8.1 Key Findings
8.2 End Users Segment: Market Attractiveness Index
8.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
8.4 Biopharma & Biotechnology Companies
8.4.1 Market Size by Region, 2026-2036 (US$ Million)
8.4.2 Market Share by Region, 2026 & 2036 (%)
8.5 Contract Development & Manufacturing Organizations (CDMOs)
8.5.1 Market Size by Region, 2026-2036 (US$ Million)
8.5.2 Market Share by Region, 2026 & 2036 (%)
8.6 Research Institutes & Academic Centers
8.6.1 Market Size by Region, 2026-2036 (US$ Million)
8.6.2 Market Share by Region, 2026 & 2036 (%)
8.7 Hospitals & Specialized Cancer Centers
8.7.1 Market Size by Region, 2026-2036 (US$ Million)
8.7.2 Market Share by Region, 2026 & 2036 (%)

9 mRNA Cancer Vaccine Market Analysis by Region
9.1 Key Findings
9.2 Regional Market Size Estimation and Forecast

10 North America mRNA Cancer Vaccine Market Analysis
10.1 Key Findings
10.2 North America mRNA Cancer Vaccine Market Attractiveness Index
10.3 North America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
10.4 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
10.5 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
10.6 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
10.7 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
10.8 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
10.9 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
10.10 U.S. mRNA Cancer Vaccine Market Analysis
10.11 Canada mRNA Cancer Vaccine Market Analysis

11 Europe mRNA Cancer Vaccine Market Analysis
11.1 Key Findings
11.2 Europe mRNA Cancer Vaccine Market Attractiveness Index
11.3 Europe mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
11.4 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
11.5 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
11.6 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
11.7 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
11.8 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
11.9 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
11.10 Germany mRNA Cancer Vaccine Market Analysis
11.11 France mRNA Cancer Vaccine Market Analysis
11.12 UK mRNA Cancer Vaccine Market Analysis
11.13 Italy mRNA Cancer Vaccine Market Analysis
11.14 Spain mRNA Cancer Vaccine Market Analysis
11.15 Rest of Europe mRNA Cancer Vaccine Market Analysis

12 Asia Pacific mRNA Cancer Vaccine Market Analysis
12.1 Key Findings
12.2 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
12.3 Asia Pacific mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
12.4 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
12.5 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
12.6 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
12.7 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
12.8 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
12.9 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
12.10 Japan mRNA Cancer Vaccine Market Analysis
12.11 China mRNA Cancer Vaccine Market Analysis
12.12 India mRNA Cancer Vaccine Market Analysis
12.13 Australia mRNA Cancer Vaccine Market Analysis
12.14 South Korea mRNA Cancer Vaccine Market Analysis
12.15 Rest of Asia Pacific mRNA Cancer Vaccine Market Analysis

13 Latin America mRNA Cancer Vaccine Market Analysis
13.1 Key Findings
13.2 Latin America mRNA Cancer Vaccine Market Attractiveness Index
13.3 Latin America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
13.4 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
13.5 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
13.6 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
13.7 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
13.8 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
13.9 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
13.10 Brazil mRNA Cancer Vaccine Market Analysis
13.11 Mexico mRNA Cancer Vaccine Market Analysis
13.12 Rest of Latin America mRNA Cancer Vaccine Market Analysis

14 MEA mRNA Cancer Vaccine Market Analysis
14.1 Key Findings
14.2 MEA mRNA Cancer Vaccine Market Attractiveness Index
14.3 MEA mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
14.4 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
14.5 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
14.6 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
14.7 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
14.8 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
14.9 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
14.10 GCC mRNA Cancer Vaccine Market Analysis
14.11 South Africa mRNA Cancer Vaccine Market Analysis
14.12 Rest of MEA mRNA Cancer Vaccine Market Analysis

15 Company Profiles
15.1 Competitive Landscape, 2026
15.2 Strategic Outlook
15.3 Moderna, Inc.
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.3.1 Net Revenue, 2021-2025
15.3.3.2 R&D, 2021-2025
15.3.3.3 Regional Market Shares, 2025
15.3.3.4 Business Segment Market Shares, 2025
15.3.4 Product Benchmarking
15.3.5 SWOT Analysis
15.3.6 Strategic Outlook
15.4 BioNTech SE
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.3.1 Net Revenue, 2021-2025
15.4.3.2 R&D, 2021-2025
15.4.4 Product Benchmarking
15.4.5 SWOT Analysis
15.4.6 Strategic Outlook
15.5 Arcturus Therapeutics, Inc.
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.3.1 Net Revenue, 2021-2025
15.5.3.2 R&D, 2021-2025
15.5.3.3 Business Segment Market Shares, 2025
15.5.4 Product Benchmarking
15.5.5 SWOT Analysis
15.5.6 Strategic Outlook
15.6 etherna
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Product Benchmarking
15.6.4 SWOT Analysis
15.6.5 Strategic Outlook
15.7 ETHRIS
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Product Benchmarking
15.7.4 Strategic Outlook
15.8 ImmmuneSensor Therapeutics
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Product Benchmarking
15.8.4 Strategic Outlook
15.9 Chimeron Bio
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Product Benchmarking
15.9.4 Strategic Outlook
15.10 Replimune Group Inc.
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Product Benchmarking
15.11 ST Pharm
15.11.1 Company Snapshot
15.11.2 Company Overview
15.11.3 Product Benchmarking
15.11.4 Strategic Outlook
15.12 Sana Biotechnology
15.12.1 Company Snapshot
15.12.2 Company Overview
15.12.3 Product Benchmarking
15.13 Cartesian Therapeutics Inc.
15.13.1 Company Snapshot
15.13.2 Company Overview
15.13.3 Financial Analysis
15.13.3.1 Net Revenue, 2021-2025
15.13.3.2 R&D, 2021-2025
15.13.4 Product Benchmarking
15.14 Strand Therapeutics
15.14.1 Company Snapshot
15.14.2 Company Overview
15.14.3 Product Benchmarking
15.14.4 Strategic Outlook
15.15 Acuitas
15.15.1 Company Snapshot
15.15.2 Company Overview
15.15.3 Product Benchmarking
15.15.4 Strategic Outlook

16 Conclusion and Recommendations
16.1 Concluding Remarks from Visiongain
16.2 Recommendations for Market Players
 
List of Tables
Table 1 mRNA Cancer Vaccine Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
Table 2 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 3 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
Table 4 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
Table 5 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 6 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 7 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 8 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 9 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 10 Other Sollid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 11 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 12 Personalized Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 13 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 14 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 15 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 16 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 17 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 18 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 19 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 20 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 21 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 22 Phase IV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 23 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 24 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 25 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 26 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 27 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 28 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 29 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 30 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 31 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 32 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 33 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 34 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 35 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 36 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 37 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 38 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 39 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 40 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 41 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 42 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 43 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 44 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 45 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 46 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 47 Spain mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 48 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 49 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 50 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 51 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 52 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 53 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 54 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 55 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 56 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 57 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 58 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 59 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 60 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 61 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 62 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 63 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 64 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 65 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 66 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 67 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 68 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 69 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 70 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 71 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 72 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 73 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 74 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 75 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 76 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 77 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 78 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
Table 79 Strategic Outlook
Table 80 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 81 Moderna, Inc.: Product Benchmarking
Table 82 Moderna, Inc.: SWOT Analysis
Table 83 Moderna, Inc.: Strategic Outlook
Table 84 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 85 BioNTech SE: Product Benchmarking
Table 86 BioNtech SE: SWOT Analysis
Table 87 BioNTech SE: Strategic Outlook
Table 88 Arcturus Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 89 Arcturus Therapeutics, Inc.: Product Benchmarking
Table 90 Arcturus Therapeutics, Inc.: SWOT Analysis
Table 91 Arcturus Therapeutics, Inc. : Strategic Outlook
Table 92 etherna: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 etherna: Product Benchmarking
Table 94 etherna: SWOT Analysis
Table 95 etherna: Strategic Outlook
Table 96 ETHRIS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 97 ETHRIS: Product Benchmarking
Table 98 ETHRIS: Strategic Outlook
Table 99 ImmmuneSensor Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 100 ImmmuneSensor Therapeutics: Product Benchmarking
Table 101 ImmmuneSensor Therapeutics: Strategic Outlook
Table 102 Chimeron Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 103 Chimeron Bio: Product Benchmarking
Table 104 Chimeron Bio: Strategic Outlook
Table 105 Replimune Group Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 106 Replimune Group Inc.: Product Benchmarking
Table 107 ST Pharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 ST Pharm: Product Benchmarking
Table 109 ST Pharm: Strategic Outlook
Table 110 Sana Biotechnology: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 Sana Biotechnology: Product Benchmarking
Table 112 Cartesian Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 113 Cartesian Therapeutics Inc.: Product Benchmarking
Table 114 Strand Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 115 Strand Therapeutics: Product Benchmarking
Table 116 Strand Therapeutics: Strategic Outlook
Table 117 Acuitas: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 118 Acuitas: Product Benchmarking
Table 119 Acuitas: Strategic Outlook

List of Figures
Figure 1 mRNA Cancer Vaccine Market Segmentation
Figure 2 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
Figure 3 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
Figure 4 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
Figure 5 mRNA Cancer Vaccine Market Attractiveness Index by Region
Figure 6 mRNA Cancer Vaccine Market: Market Dynamics
Figure 7 mRNA Cancer Vaccine Market: Impact Analysis
Figure 8 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
Figure 9 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
Figure 10 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
Figure 11 Short Term & Long Term Planning
Figure 12 Impact of U.S. and China Trade War
Figure 13 Most Impacted Countries
Figure 14 Global Market Tariff Sensitivity and Margin Pressure Analysis
Figure 15 mRNA Cancer Vaccine Market: Porter’s Five Forces Analysis
Figure 16 mRNA Cancer Vaccine Market: PEST Analysis
Figure 17 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
Figure 18 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 19 mRNA Cancer Vaccine Market Share Forecast by Indication, 2026, 2031, 2036 (%)
Figure 20 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 21 High TMB Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 22 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 23 GI Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 24 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 25 Gynecological Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 26 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 27 Breast Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 28 Other Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 29 Other Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 30 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
Figure 31 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 32 mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026, 2031, 2036 (%)
Figure 33 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 34 Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 35 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 36 Off-the-Shelf Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 37 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 38 Semi-Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 39 mRNA Cancer Vaccine Market by Therapeutic Approach: Market Attractiveness Index
Figure 40 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 41 mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026, 2031, 2036 (%)
Figure 42 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 43 Monotherapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 44 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 45 Combination Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 46 mRNA Cancer Vaccine Market by Phases: Market Attractiveness Index
Figure 47 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 48 mRNA Cancer Vaccine Market Share Forecast by Phases, 2026, 2031, 2036 (%)
Figure 49 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 50 Phase I Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 51 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 52 Phase II Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 53 Phase III Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 54 Phase III Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 55 Phase IV Segment Market Forecast by Region
Figure 56 Phase IV Segment Market Share Forecast by Region, 2029 & 2036 (%)
Figure 57 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
Figure 58 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 59 mRNA Cancer Vaccine Market Share Forecast by End Users, 2026, 2031, 2036 (%)
Figure 60 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 61 Biopharma & Biotechnology Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 62 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 63 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 64 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 65 Research Institutes & Academic Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 66 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
Figure 67 Hospitals & Specialized Cancer Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
Figure 68 mRNA Cancer Vaccine Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
Figure 69 mRNA Cancer Vaccine Market Share Forecast by Region 2026, 2031, 2036 (%)
Figure 70 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %)
Figure 71 North America mRNA Cancer Vaccine Market Attractiveness Index
Figure 72 North America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 73 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 74 North America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 75 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 76 North America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 77 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 78 North America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 79 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 80 North America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 81 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 82 North America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 83 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 84 North America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 85 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 86 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 87 Europe mRNA Cancer Vaccine Market Attractiveness Index
Figure 88 Europe mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 89 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 90 Europe mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 91 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 92 Europe mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 93 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 94 Europe mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 95 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 96 Europe mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 97 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 98 Europe mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 99 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 100 Europe mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 101 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 102 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 103 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 104 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 105 Spain mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 106 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 107 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
Figure 108 Asia Pacific mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 109 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 110 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 111 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 112 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 113 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 114 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 115 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 116 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 117 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 118 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 119 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 120 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 121 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 122 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 123 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 124 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 125 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 126 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 127 Latin America mRNA Cancer Vaccine Market Attractiveness Index
Figure 128 Latin America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 129 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 130 Latin America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 131 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 132 Latin America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 133 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 134 Latin America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 135 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 136 Latin America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 137 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 138 Latin America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 139 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 140 Latin America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 141 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 142 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 143 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 144 MEA mRNA Cancer Vaccine Market Attractiveness Index
Figure 145 MEA mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
Figure 146 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
Figure 147 MEA mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
Figure 148 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
Figure 149 MEA mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
Figure 150 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
Figure 151 MEA mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
Figure 152 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
Figure 153 MEA mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
Figure 154 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
Figure 155 MEA mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
Figure 156 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
Figure 157 MEA mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
Figure 158 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 159 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 160 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
Figure 161 mRNA Cancer Vaccine Market: Company Share/Ranking, 2026
Figure 162 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Billion, AGR%)
Figure 163 Moderna, Inc.: R&D, 2021-2025 (US$ Billion, AGR%)
Figure 164 Moderna, Inc.: Regional Market Shares, 2025
Figure 165 Moderna, Inc.: Business Segment Market Shares, 2025
Figure 166 BioNTech SE: Net Revenue, 2021-2025 (US$ Billion, AGR%)
Figure 167 BioNTech SE: R&D, 2021-2025 (US$ Billion, AGR%)
Figure 168 Arcturus Therapeutics, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 169 Arcturus Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
Figure 170 Arcturus Therapeutics, Inc.: Business Segment Market Shares, 2025
Figure 171 Cartesian Therapeutics Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
Figure 172 Cartesian Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)

List of Companies Profiled in the Report
Arcturus Therapeutics
BioNTech
Chimeron Bio
eTheRNA
Ethris GmbH
ImmuneSensor Therapeutics
Moderna
Orna Therapeutics
Replimune Group
ST Pharm
Sana Biotechnology
Cartesian Therapeutics Inc
Strand Therapeutics
Acuitas

List of Associations Mentioned in the Report
Agência Nacional de Vigilância Sanitária (ANVISA)
Biomedical Advanced Research and Development Authority (BARDA)
Coalition for Epidemic Preparedness Innovations (CEPI)
European Commission Directorate-General for Health and Food Safety (DG SANTE)
European Medicines Agency (EMA)
Food and Drug Administration Philippines (FDA Philippines)
Health Canada (Health Canada)
Institute for Clinical and Economic Review (ICER)
Medicines and Healthcare products Regulatory Agency (MHRA)
National Cancer Institute (NCI)
National Institute for Health and Care Excellence (NICE)
National Institutes of Health (NIH)
South African Medical Research Council (SAMRC)
U.S. Food and Drug Administration (FDA)